Spark Therapeutics, a gene therapy medical company, this
week signed an agreement for a headquarters in West Philadelphia. Spark
Therapeutics, spun out of Children's Hospital of Philadelphia in October with
$50 million in capital, will build out a 28,000-square-foot facility at 3737
Market St. to house its business operations, clinical research and development,
and manufacturing.
Jeffrey D. Marrazzo, cofounder and chief executive, said the
new facility "will support the continued expansion of our team and expand
our manufacturing capacity to support our clinical development and commercial
plans."
Spark anticipates moving into its new headquarters and
expanding to 50 full-time employees by the end of 2014. Spark is preparing to
complete clinical development of its lead, Phase 3 clinical program to address
inherited retinal dystrophies caused by mutations in the RPE65 gene.
Source: Philly.com
No comments:
Post a Comment